A chimeric peptide engineered from camel milk lactoferrin shows broad antimicrobial, antiviral, and anticancer activity while remaining non-toxic to normal cells and stable in blood serum.
Triple-threat peptidecLF36 demonstrated antibacterial, antiviral, and anticancer activity from a single 42-amino acid chimeric peptide engineered from camel milk lactoferrin
What the researchers found
Researchers developed cLF36, a chimeric 42-amino acid peptide combining the complete camel lactoferrampin sequence with a partial lactoferricin sequence. Testing across multiple platforms showed broad-spectrum antimicrobial activity against human, avian, and plant bacterial pathogens. The peptide also demonstrated antiviral effects against hepatitis C virus, influenza virus, and rotavirus in computational and in vitro studies.
Notably, cLF36 showed selective anticancer activity — higher toxicity against tumor cell lines than normal cells, potentially because it targets negatively charged glycosaminoglycans on tumor cell surfaces. The peptide showed no toxicity to host cells and demonstrated strong thermal and protease stability in serum, suggesting practical durability.
Why it matters
Antibiotic resistance is driving urgent demand for new antimicrobial approaches. cLF36 is interesting because it's derived from camel milk lactoferrin — an immune protein — and engineered to combine two active regions into a single more potent peptide. Its triple-threat activity (antibacterial, antiviral, anticancer) plus favorable safety and stability profile make it a promising candidate, though it remains in early research stages.
The numbers in context
42-mer chimeric peptide · Active against human, avian, and plant pathogens · Antiviral vs HCV, influenza, rotavirus · Selective tumor cell toxicity · No host cell toxicity · Serum-stable
How the study worked
Review of the research team's own multi-year body of work on cLF36, including in vitro antimicrobial testing, computational and in vitro antiviral assessments, cancer cell line studies, chicken feeding trials, and expression in prokaryotic (P170, pET) and eukaryotic (HEK293) systems.
Who was studied
Review of preclinical research — in vitro studies, computational modeling, and chicken feeding trials
What this study cannot tell us
Most evidence is preclinical — in vitro, computational, or animal (chicken) models only. No human trials. Cost-effectiveness unknown. Pharmacokinetic and pharmacodynamic profiles not yet characterized. The review summarizes work primarily from a single research group.
How to read the evidence
This is a preliminary-grade review summarizing largely preclinical evidence — in vitro assays, computational studies, and animal models. No human trials have been conducted. The results are promising but far from clinical application.
When this study was published
Published in 2024, this review consolidates several years of research on cLF36 from a single research group, representing the current state of knowledge on this specific peptide.
The bigger picture
Lactoferrin-derived peptides are part of a growing effort to develop antimicrobial alternatives to traditional antibiotics. What makes cLF36 unusual is its triple functionality — antibacterial, antiviral, and anticancer — from a single engineered peptide. If the pharmacokinetic and cost challenges can be solved, chimeric peptides like this could become versatile tools in the post-antibiotic era.
Questions still open
- Can cLF36 maintain its broad-spectrum activity in human clinical settings, or will physiological conditions reduce its effectiveness?
- Is the selective anticancer activity strong enough to be therapeutically useful, or primarily of academic interest?
- What production costs and scalability challenges stand between cLF36 and potential clinical development?
Common questions
What is lactoferrin and why is camel lactoferrin special?
How can one peptide fight bacteria, viruses, and cancer?
Read the original research
A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.
Probiotics and antimicrobial proteins, 16(5), 1886-1905
Citation
Morovati, Solmaz; Baghkheirati, Amir Asghari; Sekhavati, Mohammad Hadi; Razmyar, Jamshid. (2024). A Review on cLF36, a Novel Recombinant Antimicrobial Peptide-Derived Camel Lactoferrin.. Probiotics and antimicrobial proteins, 16(5), 1886-1905. https://doi.org/10.1007/s12602-024-10285-5